

Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non- small-cell lung cancer

Information for the public

Published: 10 March 2021

www.nice.org.uk

Pembrolizumab (Keytruda) with pemetrexed and platinum chemotherapy is available on the NHS. It is a possible treatment for untreated, metastatic, non-squamous non-small-cell lung cancer in adults if:

- their tumours have no epidermal growth factor receptor (EGFR)- or anaplastic lymphoma kinase (ALK)-positive mutations
- it is stopped at 2 years of continuous treatment or earlier if the disease progresses.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS website](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Roy Castle Lung Cancer Foundation](#), 0333 323 7200
- [British Lung Foundation](#), 03000 030 555
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 00 00

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-4040-0